4 results match your criteria: "Evansville Heart Center[Affiliation]"
A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers.
J Ocul Pharmacol Ther
October 2016
2 Inotek Pharmaceuticals Corporation , Lexington, Massachusetts.
Purpose: To investigate the safety, tolerability, and pharmacokinetics of trabodenoson, a highly selective adenosine mimetic targeting the adenosine A receptor.
Methods: In Part 1, 60 healthy adult volunteers were randomized to 14 days of twice-daily topical monocular application of placebo or trabodenoson (200, 400, 800, 1,600, 2,400, or 3,200 μg). In Part 2, 10 subjects were randomized to placebo or 8 escalating doses of bilateral trabodenoson (total daily doses: 1,800-6,400 μg).
Aortic tumour in primary anti-phospholipid syndrome.
Lancet
May 2003
Evansville Heart Center, 520 Mary Street, Evansville, Indiana 47710, USA.
Massive pulmonary embolus with pre-existing inferior vena caval filter.
Tex Heart Inst J
February 2003
Evansville Heart Center, Indiana 47710, USA.
Images in clinical medicine. Fungal prosthetic-valve endocarditis.
N Engl J Med
January 2001
Evansville Heart Center, IN 47710, USA.